Test Price
2,800 AED✅ Home Collection Available
GJB3 Gene Deafness (DFNA2B) Genetic Test in UAE – 2800 AED – NGS Full Gene Sequencing
Executive Summary & Core Metrics
This advanced genetic test analyses the entire coding region of the GJB3 (Connexin 31) gene using Next‑Generation Sequencing (NGS) to definitively diagnose autosomal dominant deafness type 2B (DFNA2B) and associated keratoderma‑deafness syndromes. The test delivers 99.9% diagnostic sensitivity and is performed in our Dubai‑based ISO 9001:2015 certified facility. The service includes VIP Mobile Phlebotomy & Temperature‑Controlled Cold‑Chain Home Collection (available daily from 8 AM to 11 PM), comprehensive post‑test clinical guidance by a DHA‑licensed Consultant Medical Geneticist, and seamless insurance pre‑approval via WhatsApp at +971 54 548 8731.
Test Overview & Methodology
The GJB3 gene encodes connexin 31, a gap junction protein critical for potassium recycling in the cochlea; pathogenic variants cause progressive sensorineural hearing loss often accompanied by palmoplantar keratoderma. Our NGS panel provides single‑nucleotide resolution and detects copy number variations (CNVs) that older methods miss, enabling definitive genetic counselling and early intervention planning within 3–4 weeks.
| Feature | Our NGS Test (GJB3 Full Gene) | Closest Alternative (Sanger Sequencing) |
|---|---|---|
| Precision | >99.9% analytical sensitivity, covers all exons ± 20 bp | ~98% sensitivity; cannot detect large deletions |
| Method | NGS + Sanger confirmation + CNV analysis | Bidirectional Sanger only |
| Turnaround | 3–4 Weeks from receipt | 5–6 Weeks for full gene |
Physician Insight & Safety Protocols
“Identifying the exact GJB3 variant empowers families with a clear roadmap for audiological intervention, genetic counselling, and future reproductive planning. However, the genetic finding must always be interpreted alongside a full audiogram, family pedigree, and clinical examination before any management decisions are made.”
— Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403
Critical Advisory
Do not discontinue or alter any prescribed hearing aids, corticosteroids for keratoderma, or other treatments without first consulting your referring specialist. Genetic testing is a diagnostic tool, not a therapeutic directive.
Exclusion Criteria & Emergency Red Flags
- Not suitable for: Patients with acute febrile illness or uncontrolled coagulopathy (increased bleeding risk during blood draw).
- Minors: Mandatory parental consent and a pre‑test genetic counselling session are required under UAE Federal Law No. 2 of 2019 concerning Use of ICT in Health Fields.
- Red Flag – Seek Immediate Medical Attention: Sudden vertigo, severe tinnitus, or acute hearing loss during the testing process; these symptoms are unrelated to routine blood collection but require urgent evaluation.
Patient FAQ & Clinical Guidance
1. What does the GJB3 genetic test detect and why is it important?
The GJB3 NGS test identifies single nucleotide variants and copy number changes in the connexin 31 gene that cause autosomal dominant non‑syndromic hearing loss DFNA2B, enabling early audiological intervention and precise genetic counselling for at‑risk relatives.
2. How is the sample collected and what are the pre‑test requirements?
A simple blood draw (3–5 mL in EDTA), a dried blood spot on an FTA card, or previously extracted genomic DNA is accepted. Mandatory pre‑test genetic counselling must be completed to document the family pedigree and obtain informed consent. Mobile phlebotomy is available daily from 8 AM to 11 PM.
3. What is the turnaround time and how are results communicated?
Final reports are delivered within 3 to 4 weeks via our secure patient portal. A telephonic post‑test discussion with a DHA‑licensed Consultant Medical Geneticist is included to interpret findings and coordinate follow‑up care.
UAE Regulatory & Data Privacy Adherence
This service complies with Federal Decree‑Law No. 45 of 2021 on Personal Data Protection (PDPL) for genomic data privacy and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields for clinical data handling. All genetic testing is performed under the ethical standards of Federal Decree‑Law No. 4 of 2016 on Medical Liability. DNA Labs UAE holds DHA Facility License Number 1143 and operates from Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE.
Clinical & Logistical Metadata
| Test Name | GJB3 Gene Deafness (DFNA2B) Genetic Test – Full Gene Sequencing |
| Price (AED) | 2,800 AED |
| Turnaround Time | 3–4 Weeks from sample receipt |
| Sample Type / Matrix | Peripheral whole blood (EDTA), dried blood spot (FTA card), or previously extracted genomic DNA. VIP Mobile Phlebotomy & Temperature‑Controlled Cold‑Chain Home Collection available daily 8 AM–11 PM. |
| Methodology Used | Next‑Generation Sequencing (NGS) with Sanger confirmation and CNV analysis |
| ICD-10-CM Code | H90.3 |
| LOINC Code | 21636-6 |
| DHA Facility License & Laboratory Address | DHA License: 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE | DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians